KalVista Pharmaceuticals Inc KALV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KALV is a good fit for your portfolio.
News
-
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
-
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
-
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
-
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
-
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
-
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
Trading Information
- Previous Close Price
- $11.50
- Day Range
- $11.27–11.78
- 52-Week Range
- $7.21–16.88
- Bid/Ask
- $11.10 / $11.60
- Market Cap
- $488.12 Mil
- Volume/Avg
- 346,978 / 846,358
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 118
- Website
- https://www.kalvista.com
Comparables
Valuation
|
Metric
|
KALV
|
EWTX
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.49 | 3.42 | 1.63 |
Price/Sales | — | — | 477.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
KALV
EWTX
PLRX
Financial Strength
|
Metric
|
KALV
|
EWTX
|
PLRX
|
|---|---|---|---|
Quick Ratio | 5.19 | 18.98 | 17.43 |
Current Ratio | 5.44 | 19.50 | 17.72 |
Interest Coverage | — | — | −145.34 |
Quick Ratio
KALV
EWTX
PLRX
Profitability
|
Metric
|
KALV
|
EWTX
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −60.93% | −24.36% | −22.68% |
Return on Equity (Normalized) | −70.84% | −25.87% | −24.50% |
Return on Invested Capital (Normalized) | −69.15% | −29.82% | −28.46% |
Return on Assets
KALV
EWTX
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wjgfvbhff | Rnmm | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xnhwcysv | Zdhqj | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zdsftzwm | Fkbhfc | $98.1 Bil | |
MRNA
| Moderna Inc | Wdlltgxcq | Qywzh | $39.1 Bil | |
ARGX
| argenx SE ADR | Zztgtnhp | Tkjj | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Kpvdpgv | Kkztq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fzhkhkgk | Dxtbgs | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cqxlzntl | Jbjjb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ycktbwqw | Fhnpcj | $12.5 Bil | |
INCY
| Incyte Corp | Yvcrrndf | Dvstlf | $11.9 Bil |